This link will take you to a Web site maintained by a third party who is solely responsible for its contents. ARIAD Pharmaceuticals, Inc. and Merck & Co., Inc. provide this link as a service to Web site visitors. ARIAD Pharmaceuticals, Inc. and Merck & Co., Inc. are not responsible for the privacy policy of any third party Web sites. We encourage you to read the privacy policy of every Web site you visit. Click CANCEL to return or OK to continue.

The information requested is intended for US healthcare professionals only.

The requested information is provided in Portable Document Format (PDF). To view and print this document you'll need to install a copy of the free Adobe^® Acrobat^® Reader^®. If you already have Adobe Acrobat Reader installed click "VIEW PDF" below. If you need the Acrobat Reader you can download it from the Adobe Acrobat Reader Download page.

If you can read this, then your browser cannot interpret Javascript. To take full advantage of what this Web site has to offer, please make sure that you have Javascript enabled in your browser preferences, or update to a browser that supports Javascript. Thank you.

Home Investigators

Healthcare Professionals Patients and Caregivers

Register for More Information

ARIAD Pharmaceuticals, Inc. and Merck & Co., Inc. are collaborating and sponsoring SUCCEED — Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Deforolimus.

To sign up for updated information about the SUCCEED trial, please complete the following information. Registration is only available to US residents.

Your privacy is important to us. Your information will only be used by ARIAD Pharmaceuticals, Inc. and Merck & Co., Inc. for purposes relating to the SUCCEED trial, and not for any other purpose except where required by law. Your information will be used and protected in accordance with the Privacy Policy.

By submitting this form, you are agreeing to receive ongoing information via e-mail regarding the SUCCEED trial.

If at any time you would like to stop receiving information and updates about the SUCCEED trial and/or sarcoma, please click here.

The SUCCEED trial Web site is intended for US residents only. It is intended for Investigators, Healthcare Professionals, and Patients and Caregivers. The use of deforolimus (AP23573, MK-8669) is limited to investigational trials. There is no guarantee that its use will be approved by the US Food and Drug Administration.